Wikidata entity: Q64836785
Quantities
| P2899 | minimum age | 18 |
| P1132 | number of participants | 27 |
| P6099 | clinical trial phase | ... | Q5452194 (phase I clinical trial) | phase I clinical trial |
| P17 | country | ... | Q30 (United States) | United States |
| P582 | end time | ... | 2021-03-17 | ??? |
| P31 | instance of | ... | Q30612 (clinical trial) | clinical trial |
| P1050 | medical condition | ... | Q33525 (carcinoma) | carcinoma |
| P4844 | research intervention | ... | Q13896859 (pembrolizumab) | pembrolizumab |
| P6153 | research site | ... | Q219563 (University of Washington) | University of Washington |
| P859 | sponsor | ... | Q219563 (University of Washington) | University of Washington |
| P580 | start time | ... | 2018-08-28 | ??? |
| P8363 | study type | ... | Q78089383 (interventional study) | interventional study |
| P1476 | title | Monolingualtext | A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma | ??? |
| P3098 | ClinicalTrials.gov ID | NCT03260504 |
Why not click here or view trends?
log id: 5302016